drugset / Trial / NCT01591330

A Study of LY2140023 in Healthy Males and Females

NCT01591330

Phase 1 Completed 35 enrolled Denovo Biopharma LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The study will evaluate the effect of different particle size of LY2140023. The study involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a washout period of at least 3 days between doses. This study will last approximately 60 days not including screening. Screening is required within 30 days prior to study entry.

Timeline

Start
2012-04
Primary completion
2012-06
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2140023 Unknown 80 mg Oral

Indications

No indication recorded.